Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05508867 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Name: A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008) — clinical trial record (NCT05508867)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhasePhase 2

SponsorMerck Sharp & Dohme LLC

Started2022-10-18

View on ClinicalTrials.gov ↗

Researchers are looking for a way to treat classical Hodgkin lymphoma (cHL) that is relapsed (the cancer has come back after treatment) or refractory (current treatment has stopped working to slow or stop cancer growth). Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive chemotherapy.

Amendment history 1 change detected by DataLookout

2026-09-02

Results posted: 2026-09-01

Trial Details

NCT Number	NCT05508867
Lead Sponsor	Merck Sharp & Dohme LLC
Conditions	Hodgkin Lymphoma
Enrollment	203 participants
Start Date	2022-10-18
Primary Completion	2025-09-03 (estimated)
Study Completion	2026-01-08 (estimated)
Updated on ClinicalTrials.gov	2026-09-01